| scholarly article | Q13442814 |
| P50 | author | Joakim Dillner | Q62918677 |
| P2093 | author name string | Matti Lehtinen | |
| P2860 | cites work | Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008 | Q64129516 |
| Mumps and rubella eliminated from Finland | Q73210068 | ||
| Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study | Q81025210 | ||
| Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN | Q81166443 | ||
| Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women | Q83053843 | ||
| Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up | Q83428460 | ||
| Impact of human papillomavirus vaccination depends on effective vaccination strategy | Q84025518 | ||
| Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine | Q84156757 | ||
| Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women | Q84193727 | ||
| An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in health | Q84969602 | ||
| Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses | Q21144710 | ||
| Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate | Q24288709 | ||
| Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males | Q24614644 | ||
| Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States | Q24655328 | ||
| The papillomavirus life cycle | Q28238578 | ||
| Condom use and the risk of genital human papillomavirus infection in young women | Q28247581 | ||
| Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years | Q28255234 | ||
| Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 | ||
| Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda | Q28743450 | ||
| Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial | Q28750269 | ||
| Epidemiology of Genital Human Papillomavirus Infection | Q56144870 | ||
| A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions | Q56770293 | ||
| Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes | Q56987878 | ||
| Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer | Q58279938 | ||
| Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer | Q58280280 | ||
| Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries | Q30230410 | ||
| Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark | Q30416264 | ||
| Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma | Q31812746 | ||
| Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review | Q33689529 | ||
| Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials | Q33699365 | ||
| Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data | Q33743738 | ||
| Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity | Q33797578 | ||
| Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students | Q33963919 | ||
| Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine | Q34032367 | ||
| Addressing the vaccine confidence gap. | Q34191703 | ||
| Role of herd immunity in determining the effect of vaccines against sexually transmitted disease | Q34380787 | ||
| HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays | Q34542304 | ||
| Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only | Q34568949 | ||
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
| Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? | Q34971126 | ||
| Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men | Q35054958 | ||
| Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica | Q35093306 | ||
| HPV - immune response to infection and vaccination | Q35180148 | ||
| Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial | Q35212868 | ||
| Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study | Q35567403 | ||
| Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia | Q35656638 | ||
| Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica | Q35967430 | ||
| Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera | Q35985515 | ||
| Sound efficacy of prophylactic HPV vaccination: Basics and implications | Q36373404 | ||
| High-risk HPV type-specific clearance rates in cervical screening | Q36610417 | ||
| Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. | Q36611591 | ||
| High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
| Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study | Q36645631 | ||
| Comparing the performance of six human papillomavirus tests in a screening population | Q36663594 | ||
| Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. | Q36734952 | ||
| CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples | Q36948137 | ||
| Human papillomavirus vaccination in males | Q36972163 | ||
| Updating the natural history of human papillomavirus and anogenital cancers | Q36979148 | ||
| Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 | Q37223672 | ||
| Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline | Q37223983 | ||
| Prospects for new human papillomavirus vaccines | Q37635638 | ||
| Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines | Q37838646 | ||
| Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study | Q37846849 | ||
| Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. | Q37847260 | ||
| High-throughput monitoring of human papillomavirus type distribution | Q37847498 | ||
| Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection | Q37855949 | ||
| Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks | Q37855991 | ||
| Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers | Q37864690 | ||
| Chlamydia trachomatis infection and persistence of human papillomavirus | Q37865331 | ||
| Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior | Q37884955 | ||
| Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine | Q37942643 | ||
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Q38383523 | ||
| Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women | Q38872908 | ||
| Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up | Q39514544 | ||
| Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women | Q39866095 | ||
| Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines | Q40430523 | ||
| IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo | Q41996237 | ||
| The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays | Q42859721 | ||
| Cancers attributable to human papillomavirus infection | Q42933914 | ||
| Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years | Q43415471 | ||
| Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck | Q43571689 | ||
| Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s | Q43620361 | ||
| Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women | Q43655015 | ||
| Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. | Q44038372 | ||
| Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. | Q44133307 | ||
| Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination | Q44170367 | ||
| Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study | Q44222617 | ||
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial | Q44350321 | ||
| A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 | ||
| Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study | Q44522163 | ||
| Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay | Q44539557 | ||
| Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination | Q44576798 | ||
| Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches | Q44759395 | ||
| Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women | Q45399287 | ||
| Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant | Q45403548 | ||
| Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine | Q45404033 | ||
| Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years | Q46214415 | ||
| HPV vaccine against anal HPV infection and anal intraepithelial neoplasia | Q46421186 | ||
| Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes | Q46648097 | ||
| Just implementation of human papillomavirus vaccination | Q48529470 | ||
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial | Q49169372 | ||
| Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. | Q51903894 | ||
| HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. | Q51961251 | ||
| Effect of smoking cessation on cervical lesion size. | Q52306837 | ||
| Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. | Q53425602 | ||
| Human papillomavirus infections with multiple types and risk of cervical neoplasia. | Q53612097 | ||
| Childhood vaccination and type 1 diabetes. | Q55038338 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HPV vaccine | Q900189 |
| P304 | page(s) | 400-410 | |
| P577 | publication date | 2013-06-04 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Clinical trials of human papillomavirus vaccines and beyond | |
| P478 | volume | 10 |
| Q38136802 | Adolescents and vaccines in the western world |
| Q92995500 | Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? |
| Q92604146 | Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women |
| Q38838178 | An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression |
| Q26769069 | Anal cancer and intraepithelial neoplasia screening: A review |
| Q92992913 | Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK |
| Q57148888 | Association between Human Papillomavirus and Non-cervical Genital Cancers in Brazil: A Systematic Review and Meta-Analysis |
| Q37073299 | Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles |
| Q52650189 | Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. |
| Q42517431 | Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort |
| Q42255129 | Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? |
| Q44863515 | Carcinogenic human papillomavirus infection |
| Q40112605 | Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends |
| Q40432574 | Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference |
| Q41541977 | Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. |
| Q38599579 | Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study |
| Q92705378 | Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine |
| Q34389227 | Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses |
| Q35221177 | Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial |
| Q26782499 | Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma |
| Q54223705 | Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. |
| Q30239987 | Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice |
| Q54216892 | Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance. |
| Q38549643 | Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies |
| Q34275134 | Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine |
| Q38206887 | HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases |
| Q46902171 | HPV-FASTER: broadening the scope for prevention of HPV-related cancer |
| Q40175248 | HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy. |
| Q30794549 | HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology |
| Q26770541 | Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies |
| Q39020800 | Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer |
| Q39278938 | Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs |
| Q40784316 | Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines |
| Q92585076 | Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status |
| Q40152615 | Human papillomavirus related oropharyngeal cancer |
| Q89915009 | Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial |
| Q35658358 | Immunogenicity of infectious pathogens and vaccine antigens |
| Q37135163 | Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer |
| Q94501507 | Impact of HPV vaccination on cervical screening performance: a population-based cohort study |
| Q47603242 | Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). |
| Q33929216 | Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study |
| Q51731914 | Impacts of human papillomavirus vaccination for different populations: A modelling study. |
| Q90559323 | Maximising the potential of HPV vaccines |
| Q97526303 | Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches |
| Q35861286 | Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype |
| Q36736614 | Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. |
| Q91783484 | PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells |
| Q90015576 | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
| Q58112348 | Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule |
| Q38460201 | Present status of human papillomavirus vaccine development and implementation |
| Q51811189 | Prevention of HPV disease burden. |
| Q54217505 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. |
| Q35818648 | Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine |
| Q44701708 | Reply to Ryser et al. |
| Q35129114 | Revealing the density of encoded functions in a viral RNA |
| Q33891821 | Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies |
| Q37561432 | Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial. |
| Q38716676 | Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis |
| Q90238817 | Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway |
| Q38618078 | Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. |
| Q38997255 | The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases |
| Q38869506 | Therapeutic potential of an AcHERV-HPV L1 DNA vaccine. |
| Q39955058 | Trends in the Incidence of Oropharyngeal Cancers in the United States |
| Q48345981 | Vaccination protects against invasive HPV-associated cancers |
| Q90251587 | Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied |
| Q38859779 | Worldwide burden of cancer attributable to HPV by site, country and HPV type. |
Search more.